Options in the clinical treatment of obesity

The clinical management of obesity is undergoing continued change as new device and drug options are being developed and introduced alongside developing surgical options.

1.  Pharmaceutical Treatment of Obesity: Past, Present and Future Drugs
a.  Promising Drugs That Have Failed
i.  Phentermine/Fenfluramine Combination
ii.  Abbott’s Meridia (Sibutramine)
iii.  Vivus’ Qnexa
iv.  Arena’s Lorqess
b.  Prescription Drugs Currently on the Market
i  Appetite Suppression Drugs
ii.  Malabsorption Drugs
iii.  Satiety Drugs
·  Amylin’s Byetta Off-Label for Obesity
·  Novo Nordisk’s Victoza Off-Label for Obesity
iv.  Combination Drugs
c.  Areas of Pharmaceutical Research
i.  Melanocortin Receptor System
ii.  Cannabinoid Receptor Antagonists
iii.  GLP-1 Analogs
iv.  Methionine Aminopeptidase 2 (MetAP2) Inhibitor
v.  Appetite Suppression Drugs
·  Lorcaserin
·  NeuroSearch’s Tesofensine
·  Shionogi’s Velneperit
vi.  Malabsorption Drugs
vii.  Satiety Drugs
viii.  Combination Drugs
2.  Non- Pharmaceutical Options for Treating Obesity
a.  Metabolic/Bariatric Surgery
i.  Vertical Banded Gastroplasty
ii.  Roux-en-Y Surgery
iii.  Sleeve Gastrectomy
iv.  Biliopancreatic Diversion with Duodenal Switch
v.  Jejuno-ileal Bypass: An Obsolete Procedure
b.  Devices to Treat Obesity
i.  Restrictive Devices
·  Adjustable Gastric Banding
·  Transoral Gastroplasty (TOGA)
·  RESTORe Suturing System™
ii.  Artificial Fullness Devices
iii.  Malabsorption Devices
·  GI Dynamics’ EndoBarrier
·  Gastrx Sleeve-like Device
·  ValenTx Sleeve
iv.  Devices to Control Gastric Emptying
·  BAROnova Therapeutics’ TransPyloric Shuttle
·  BaroSense’s TERIS (Trans-oral Endoscopic Restrictive Implant System)
·  Endoscopic Intragastric Injection of Botulinum Toxin
v.  Appetite Suppressive Devices
·  MetaCure’s Tantalus System
·  EnteroMedics’ Maestro System for VBLOC
·  Silhouette Medical’s nObese RF Ablation Device
vi.  Gastric Electrical Stimulation
The products, technologies, companies and markets in the field of obesity management is the subject of the global MedMarket Diligence Report #S835, "Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2011-2019," described below and at link:
This report is a detailed market and technology assessment and forecast of the products and technologies in the clinical management of obesity (bariatrics). The report describes the current and projected patient population in obesity, detailing their incidence worldwide, with available incidence by country for the U.S., major European countries, major countries in Asia/Pacific (including Japan, China, India and Australia), the clinical practices in their management to encompass surgical approaches, medical supervised severely restricted diets, drug therapies, OTC treatments, biopharmaceuticals, non-pharmacologic approaches and weight maintenance approaches. The report describes clinical trends in the management of the obese. The report details the products on the market and the status of those in development for bariatric surgery, drug therapy, gastric stimulation devices, brain stimulation devices, combination therapies and genetic therapy and other therapies under development, and will provide current and worldwide market forecasts (2009-2019) separately for pharmaceuticals (with separate segment forecast data for satiety, malabsorption, appetite suppression and combination drugs) and devices (with separate segment forecast data for stomach restriction artificial fullness, malabsorption, gastric emptying and appetite suppression), with current (2009) market shares of the leading competitors in each segment. The report profiles the 45 leading competitors, detailing current and potential position in the market, their products and their market strengths and likelihood of future success.

Leave a Reply